SFIN - Safetek International, Inc. (OTCBB: SFIN) focuses on screening new technologies in the life sciences and health care fields. Its subsidiary, Oriens Life Sciences, Ltd., serves as a platform for the company to screen the Israeli life sciences and health care industry, as well as identify, analyze, and acquire or invest in technologies in life sciences and health care fields. In addition, the company has an option to purchase license for all intellectual property rights in Thrombin inhibition compounds of Matrix Pharma, Inc. It intends to develop a technology that will assist and accelerate the identification of new generation of lead compounds stimulating the activity of muscarinic receptors, for the development of new therapies for various diseases, such as Alzheimer's disease, glaucoma, and over active bladder. The company was incorporated in 1988 as Theoretics, Inc. and changed its name to Safetek International, Inc. in 1989. Safetek International is based in Tel Aviv, Israel.
